Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers

NCT02273414 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BIIL 284 BS - rising dose
DRUG: Placebo

Sponsor

Boehringer Ingelheim